✦ LIBER ✦

Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease

✍ Scribed by Kyriaki Mystakidou; Evangelia Stathopoulou; Efi Parpa; Vassilios Kouloulias; Evangelia Kouskouni; Lambros Vlahos

Publisher: Springer-Verlag
Year: 2008
Tongue: English
Weight: 324 KB
Volume: 134
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-008-0419-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of oral ibandronate c

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy

✍ E. Cock; J. Hutton; P. Canney; J. J. Body; P. Barrett-Lee; M. P. Neary; G. Lewis 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 200 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi